NASDAQ$BCYC
Bicycle Therapeutics plc · Q1 2023 earnings
Q1 2023 earnings · · Investor relations
Briefing
Reported financial results for the first quarter ended March 31, 2023.
Bicycle Therapeutics reported encouraging Phase I dose escalation results from BT8009, showing anti-tumor activity in heavily pre-treated cancer patients. They also entered into multiple research and development collaborations to develop Bicycle® radio-conjugates, expanding their oncology strategy.
- Reported encouraging Phase I dose escalation results from BT8009.
- BT8009 showed anti-tumor activity in heavily pre-treated urothelial, lung and breast cancer patients.
- Entered into a strategic collaboration with Novartis.
- Expanded collaboration with the Division of Radiopharmaceutical Chemistry, German Cancer Research Center to develop Bicycle® Radio-Conjugates.
Headline financials
Revenue & EPS history
Bicycle · Revenue · Quarterly
$4.9M
Forward guidance
Bicycle Therapeutics anticipates advancement of its product candidates, including BT8009, BT5528 and BT7480; the anticipated dosing in and progression of Bicycle’s clinical trials; the availability of and timing of announcement of data from clinical trials and regulatory updates for clinical candidates; statements regarding Bicycle’s collaborations with Novartis, and DKFZ; the discovery, development and potential commercialization of potential radiopharmaceutical or other product candidates using Bicycle’s technology under the strategic collaboration agreements; Bicycle’s intent to commence initial testing of its wholly owned BRCs in patients by the end of 2024; the therapeutic potential for Bicycles in oncology and other applications; and Bicycle’s expected financial runway.
Tailwinds
- Anticipated advancement of product candidates, including BT8009, BT5528 and BT7480
- The anticipated dosing in and progression of Bicycle’s clinical trials
- The availability of and timing of announcement of data from clinical trials and regulatory updates for clinical candidates
- Statements regarding Bicycle’s collaborations with Novartis, and DKFZ
- Bicycle’s intent to commence initial testing of its wholly owned BRCs in patients by the end of 2024
Headwinds
- Uncertainties inherent in the initiation, progress and completion of clinical trials and clinical development of Bicycle’s product candidates
- The risk that Bicycle may not realize the intended benefits of its technology
- Availability and timing of results from clinical trials
- Whether the outcomes of preclinical studies will be predictive of clinical trial results
- The risk that Bicycle’s projections regarding its expected financial runway are inaccurate or that its conduct of its business requires more cash than anticipated
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q1 2023
+1.2%
Avg return
Earnings day
-1.6%
Avg return
5 days after
+0.1%
Avg return
30 days after
52%
14 / 27 earnings
Positive
+19.3%
Q4 2019
Best reaction
-10.8%
Q1 2022
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -0.2% | +3.6% | -0.8% | |
| Q4 2025 | -4.2% | -13.9% | +1.8% | |
| Q3 2025 | +6.7% | -16.0% | -8.6% | |
| Q1 2025 | +6.1% | -13.6% | -4.0% | |
| Q4 2024 | -1.3% | -2.5% | -18.3% | |
| Q3 2024 | -5.5% | -2.2% | -15.1% | |
| Q2 2024 | -0.7% | +2.1% | -10.0% | |
| Q1 2024 | +1.6% | -4.6% | -8.3% | |
| Q4 2023 | +3.1% | +9.5% | +14.9% | |
| Q3 2023 | +1.2% | -0.7% | -2.3% | |
| Q2 2023 | +1.3% | -2.8% | -4.1% | |
| Q1 2023 | -0.4% | +2.5% | +15.7% | |
| Q4 2022 | -1.9% | -5.5% | -6.2% | |
| Q3 2022 | -3.2% | +0.8% | +29.6% | |
| Q2 2022 | +14.8% | +17.7% | +12.8% | |
| Q1 2022 | -10.8% | -22.6% | -33.6% | |
| Q4 2021 | -1.2% | -9.7% | -7.6% | |
| Q3 2021 | +0.7% | +2.5% | -6.8% | |
| Q2 2021 | +1.8% | +2.3% | +36.0% | |
| Q1 2021 | +1.9% | -1.3% | -5.5% | |
| Q4 2020 | +1.9% | +2.0% | +3.8% | |
| Q3 2020 | -1.5% | +3.1% | +5.2% | |
| Q2 2020 | -0.2% | +0.0% | +5.8% | |
| Q1 2020 | +0.7% | +6.6% | +23.2% | |
| Q4 2019 | +19.3% | +1.5% | -2.3% | |
| Q3 2019 | -4.2% | -7.7% | -4.8% | |
| Q2 2019 | +5.9% | +5.4% | -6.6% | |
| Q1 2019 | — | — | — | |
| Q4 2018 | — | — | — | |
| Q3 2018 | — | — | — | |
| Q2 2018 | — | — | — | |
| Q1 2018 | — | — | — | |
| Q4 2017 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro